Research Site

Salford M8 8HD

2 studies enrolling now · 14 studies all time

What they study most

Acute Coronary Syndrome, COVID-19, Chronic Kidney Disease, Chronic Kidney Disease and Hypertension, Dermatomyositis, Hyperkalemia, Hyperparathyroidism, Secondary, Immunoglobulin A Nephropathy, Lupus Nephritis, Migraine Disorders, Primary Membranous Nephropathy, Relapsing Multiple Sclerosis

Studies at this site

• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Recruiting now
• Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) — Recruiting now
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) — Stopped early
• Tracking Treatment Pathways in Adult Patients With Hyperkalemia. — Completed
• Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis — Stopped early
• Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) — Stopped early
• Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. — Completed
• Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger — Stopped early
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease — Completed
• Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine — Completed
• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis — Completed
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis — Completed
• Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis — Completed